HVAC Covid-19 vaccines
While Covid-19 pandemic has impacted the HVAC industry in more ways than one, with some businesses still thriving in the uncertain circumstances. In fact, U.S. industrial OEM Evapco, which makes low-charge packaged ammonia (R717) systems, expects its business to grow significantly as the effects of the pandemic wear off in 2021. According to the company’s vice president Kurt Liebendorfer, the numerous large capital projects that have been postponed due to COVID-19 are likely to be suspended once things return to normal.
This won’t come as a big surprise as the HVAC industry is playing an important role in ending this crisis. Now that vaccines are already being distributed around the world, many will be using the industry’s services to store and transport the vaccines.
For example, in Athens, Ohio, Stirling Ultracold has developed novel cooling technology for freezers to accommodate the Pfizer / BioNTech and Moderna vaccines, both of which require specific temperatures to maintain effectiveness.
Five-year-old Austrian engineering and manufacturing company Mirai Intex has also contributed its know-how and will house the Pfizer / BioNTech vaccine in its ultra-low temperature systems that use air (R729) from the atmosphere as a refrigerant and deliver temperatures as low as -110 ° C (-166 ° F).
In addition, cold chain systems are also important in ending the pandemic. Fortunately, the SolarChill project is already complete with at least 100,000 vaccine coolers in places with no reliable power supply. The units use electricity from solar energy and hydrocarbons (isobutane / R600a) as a refrigerant to maintain temperatures between 2 ° C and 8 ° C (46 ° C), enough until the shocks are delivered to individuals.
But while the vaccines are still running, HVAC equipment will of course continue to play a role in preventing the virus from spreading indoors.
Click below to read the magazine
Click here to download the magazine
Click here to read more about Yumpu
Click here to read on ISSUU